The chronic lymphocytic leukemia international prognostic index (CLL-IPI) was recently developed for the prediction of overall survival, using data from approximately 3500 patients. The CLL-IPI can also predict time-to-first treatment failure in patients with newly diagnosed disease.
In a letter published in Blood, researchers in Italy describe how they evaluated the validity and reproducibility of the CLL-IPI in an independent cohort of 1364 newly diagnosed and non-referred patients.1
According to the CLL-IPI, 471 patients were classified as low-risk, 214 as intermediate-risk, 139 as high-risk, and 34 as very high-risk, with stratification demonstrated significant differences in overall survival among the prognostic groups.
Continue Reading
Median 5-year and 10-year overall survival rates by CLL-IPI category were similar to those originally observed in the initial Mayo Clinic study, suggesting that survival estimates provided by the CLL-IPI are reproducible.
RELATED: Ofatumumab Active for Induction and Maintenance in Untreated CLL
The researchers compared the CLL-IPI with MDACC index score for predicting overall survival and time-to-first treatment failure in newly diagnosed patients.
The CLL-IPI has higher prognostic accuracy for predicting overall survival than the MDACC index score, and the CLL-IPI appeared to better predict progression than the MDACC score.
Reference
- Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index: Analysis of 1364 newly diagnosed patients. Blood. 2016 Aug 22. doi: 10.1182/blood-2016-07-728261 [Epub ahead of print]
